Form D · Biotechnology
Sentrimed, Inc.
Mullica Hill, NJ · CIK 0002014313
Offering snapshot reported May 13, 2026 · SEC filing
- Reported sold
- $250K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2026 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Mar 7, 2024 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583894
Source: Form D, filed May 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tabbetha Dobbins | Director |
| Bradley Galer | Director |
| Gary Goldberg | Executive |
| Jack Goldberg | Director, Executive |
| Christopher Leonard | Executive |
| William Ragatz | Director, Executive |
| Mari Rhodehamel Yin | Director, Executive |
| Arye Rosen | Executive |
| Mari Rhodehamel Yin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
107 Gilbreth Parkway
Mullica Hill, NJ, 08062
Mullica Hill, NJ, 08062